Gary D. Swergold

4.5k total citations · 1 hit paper
29 papers, 2.8k citations indexed

About

Gary D. Swergold is a scholar working on Molecular Biology, Plant Science and Surgery. According to data from OpenAlex, Gary D. Swergold has authored 29 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 14 papers in Plant Science and 4 papers in Surgery. Recurrent topics in Gary D. Swergold's work include Chromosomal and Genetic Variations (13 papers), RNA and protein synthesis mechanisms (10 papers) and RNA Interference and Gene Delivery (6 papers). Gary D. Swergold is often cited by papers focused on Chromosomal and Genetic Variations (13 papers), RNA and protein synthesis mechanisms (10 papers) and RNA Interference and Gene Delivery (6 papers). Gary D. Swergold collaborates with scholars based in United States, Australia and Germany. Gary D. Swergold's co-authors include Evan A. Stein, Maxine Singer, Ronald E. Thayer, Beth A. Dombroski, Igor V. Ovchinnikov, Ralph J. DeBerardinis, Thierry Naas, Abram Gabriel, Michelle L. Kimberland and Haig H. Kazazian and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Gary D. Swergold

29 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

2012 505 citations Evan A. Stein, Scott Mellis et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary D. Swergold United States	22	1.8k	1.3k	538	392	192	29	2.8k
Walid G. Yasmineh United States	22	956 0.5×	593 0.5×	182 0.3×	369 0.9×	85 0.4×	52	1.8k
Xiaodong Xie China	19	893 0.5×	262 0.2×	111 0.2×	72 0.2×	162 0.8×	78	1.5k
Andrew R. Harper United Kingdom	15	363 0.2×	169 0.1×	86 0.2×	104 0.3×	37 0.2×	41	939
David M. Nelson United States	24	2.0k 1.1×	148 0.1×	97 0.2×	309 0.8×	322 1.7×	45	2.9k
Han Sun China	22	1.3k 0.7×	141 0.1×	130 0.2×	172 0.4×	171 0.9×	106	2.0k
Claudio Schneider Italy	21	771 0.4×	40 0.0×	122 0.2×	82 0.2×	189 1.0×	41	1.4k
Shipra Agrawal United States	23	1.0k 0.5×	146 0.1×	136 0.3×	124 0.3×	93 0.5×	44	1.8k
Zhen Jiang China	17	1.3k 0.7×	218 0.2×	142 0.3×	29 0.1×	83 0.4×	55	1.9k
Ernst Steyrer Austria	21	572 0.3×	41 0.0×	443 0.8×	172 0.4×	80 0.4×	34	1.5k
В. В. Носиков Russia	22	764 0.4×	47 0.0×	156 0.3×	319 0.8×	152 0.8×	101	1.6k

Countries citing papers authored by Gary D. Swergold

Since Specialization

Citations

This map shows the geographic impact of Gary D. Swergold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary D. Swergold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary D. Swergold more than expected).

Fields of papers citing papers by Gary D. Swergold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary D. Swergold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary D. Swergold. The network helps show where Gary D. Swergold may publish in the future.

Co-authorship network of co-authors of Gary D. Swergold

This figure shows the co-authorship network connecting the top 25 collaborators of Gary D. Swergold. A scholar is included among the top collaborators of Gary D. Swergold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary D. Swergold. Gary D. Swergold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stein, Evan A. & Gary D. Swergold. (2013). Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics. Current Atherosclerosis Reports. 15(3). 310–310. 65 indexed citations

Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. Obstetrical & Gynecological Survey. 67(7). 413–414. 10 indexed citations

Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. New England Journal of Medicine. 366(12). 1108–1118. 505 indexed citations breakdown →

Swergold, Gary D., W. Smith, Scott Mellis, et al.. (2011). Abstract 16265: Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 With a Monoclonal Antibody REGN727/SAR236553, Effectively Reduces Low-Density-Lipoprotein Cholesterol, as Mono or Add-on Therapy in Heterozygous Familial and Non Familial Hypercholesterolemia. Circulation. 124. 6 indexed citations

Swergold, Gary D., et al.. (2011). REGN727/SAR236553, A FULLY HUMAN PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) MONOCLONAL ANTIBODY: EFFECTS ON SAFETY AND LIPID AND LIPOPROTEIN PROFILES WHEN ADMINISTERED SUBCUTANEOUSLY. Journal of the American College of Cardiology. 57(14). E2023–E2023. 3 indexed citations

Krum, Henry, Gary D. Swergold, Arnold R. Gammaitoni, et al.. (2011). Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. Cardiovascular Therapeutics. 30(6). 342–350. 24 indexed citations

Swergold, Gary D., et al.. (2010). Abstract 23251: Safety, Lipid, and Lipoprotein Effects of REGN727/SAR236553, a Fully-Human Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Monoclonal Antibody Administered Intravenously to Healthy Volunteers. Circulation. 122. 5 indexed citations

Krum, Henry, Gary D. Swergold, Sean Curtis, et al.. (2009). Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. Journal of Hypertension. 27(4). 886–893. 41 indexed citations

Swergold, Gary D., James S. McLay, Tim McCarthy, et al.. (2009). Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Lara D. Veeken. 48(4). 425–432. 58 indexed citations

10.

Keller, Steven M., et al.. (2009). Diagnosis of palmar hyperhidrosis via questionnaire without physical examination. Clinical Autonomic Research. 19(3). 175–181. 13 indexed citations

11.

Zhu, Lingxiang, Gary D. Swergold, & Michael F. Seldin. (2003). Examination of sequence homology between human chromosome 20 and the mouse genome: intense conservation of many genomic elements. Human Genetics. 113(1). 60–70. 16 indexed citations

12.

Mathews, Lauren, et al.. (2003). Large Differences between LINE-1 Amplification Rates in the Human and Chimpanzee Lineages. The American Journal of Human Genetics. 72(3). 739–748. 25 indexed citations

13.

Myers, Jeremy S., Bethaney Vincent, W. Scott Watkins, et al.. (2002). A Comprehensive Analysis of Recently Integrated Human Ta L1 Elements. The American Journal of Human Genetics. 71(2). 312–326. 120 indexed citations

14.

Ovchinnikov, Igor V., Andrea B. Troxel, & Gary D. Swergold. (2001). Genomic Characterization of Recent Human LINE-1 Insertions: Evidence Supporting Random Insertion. Genome Research. 11(12). 2050–2058. 93 indexed citations

15.

Sheen, Fang-miin, Stephen T. Sherry, Myles B. Robichaux, et al.. (2000). Reading between the LINEs: Human Genomic Variation Induced by LINE-1 Retrotransposition. Genome Research. 10(10). 1496–1508. 105 indexed citations

16.

Dombroski, Beth A., John V. Moran, Michelle L. Kimberland, et al.. (1997). Many human L1 elements are capable of retrotransposition. Nature Genetics. 16(1). 37–43. 361 indexed citations

17.

Singer, Maxine, et al.. (1993). LINE-1: a human transposable element. Gene. 135(1-2). 183–188. 55 indexed citations

18.

Becker, Kevin G., et al.. (1993). Binding of the ubiquitous nuclear transcription factor YY1 to a cis regulatory sequence in the human LINE-1 transposable element. Human Molecular Genetics. 2(10). 1697–1702. 114 indexed citations

19.

Swergold, Gary D.. (1990). Identification, Characterization, and Cell Specificity of a Human LINE-1 Promoter. Molecular and Cellular Biology. 10(12). 6718–6729. 56 indexed citations

20.

Swergold, Gary D.. (1990). Identification, characterization, and cell specificity of a human LINE-1 promoter.. Molecular and Cellular Biology. 10(12). 6718–6729. 345 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact